glp 1 gip 1 Frontiers PDB-101: Molecule of the Month:
Description
, decrease
Pharmaceutical manufacturers in the country, including Novo Nordisk, have assured diabetes patients that there is no current impact of COVID-19 on their supply chain
If you have a history of significant GI issues or poor tolerance to other medications, semaglutide lower discontinuation rate (5-7% vs 12-18%) suggests better overall tolerability
If future clinical trials confirm a protective effect, GLP-1 medications could represent a new approach to breast cancer prevention, particularly among those already using the drugs for obesity or diabetes
2025 Jun 1;26(11):5338
